PBYIPuma Biotechnology, Inc.
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.
Priced for ~1% a year FCF growth. The price bakes in little to no growth.
Expensive vs its own history: P/E 21.2 vs a 10.3 median over 14 quarters (+107% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PBYI's price assumes
Puma Biotechnology, Inc. trades at 21.2× earnings against 19.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 19.8 · 1.07× the median: the market pays up for this one
- Price / sales
- 1.85
Price / sales · as of 2026-Q2
- Free cash flow yield
- 7.2%
Free cash flow yield · Biotechnology median 4.3%
- Growth the price implies
- +0.77%
Growth the price implies · The price pays for +0.77% free cash flow growth a year for a decade; revenue has held flat over the last three.
Details›
- Price / bookas of 2026-Q2
- 3.08
- EV / EBITas of 2026-Q2
- 14.3
- EV / salesas of 2026-Q2
- 1.88
- Healthcare median P/E503 names
- 27.9
- Biotechnology median P/E242 names
- 19.8
- Free cash flow, trailing twelve months
- $41M
- Market capitalisation51.6 million shares, counted Aug 3, 2026
- $569M
- 3-year revenue growth
- +0.16%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 21.2× today against a 10.3× median |
| 52-week range | $4.73 – $11.28 |
| Today | $11.03 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.